RADNOR, Pa., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Wells Fargo Securities Healthcare Conference in Boston, Massachusetts on Thursday, September 7, 2023 at 8:45 a.m. ET.
The live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcast will be available on the Company’s website for approximately 90 days.
Wells Fargo Securities Healthcare Conference:
| Date: | Thursday, September 7, 2023 |
| Time: | 8:45 a.m. ET |
| Webcast Link |
About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$42.97 |
| Daily Change: | -0.38 -0.88 |
| Daily Volume: | 1,481,548 |
| Market Cap: | US$3.330B |
September 30, 2025 September 02, 2025 August 12, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
